New law reduces drug prices for seniors - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Health/Employee Benefits News
Newswires RSS Get our newsletter
Order Prints
September 21, 2022 Newswires
Share
Share
Post
Email

New law reduces drug prices for seniors

Sandusky Register (OH)

SANDUSKY — Drug prices for seniors will be reined in under legislation approved by Congress and recently signed into law by President Joe Biden.

The AARP, which had lobbied for the changes, reported in the September AARP Bulletin that the Inflation Reduction Act, as Democrats dubbed the measure, could save older Americans billions of dollars in drug costs.

According to the AARP, the new law will set an annual limit of $2,500 for out-of-pocket drug costs for about 50 million Medicare enrollees who have Part D prescription drug coverage. The annual limit takes effect in 2025.

The AARP also says the law imposes tax penalties on drug companies that raise drug prices more than the inflation rate. The cost of Medicare-covered insulin is capped at $35 a month, and out-of-pocket costs for most vaccines under Medicare are eliminated.

Premiums for Part D drug insurance plans won't rise more than 6 percent a year through at least 2029.

One important provision of the new law is that the federal government, leveraging the bargaining power it has from the huge amounts of drugs it purchases for Medicare, will begin negotiating the price of ten high-cost prescription drugs in 2023. The number of drugs whose prices are negotiated goes up to 15 in 2027 and 20 in 2029.

Negotiating prices for drugs purchased for Medicare is a goal that's long been sought by Democrats.

The resulting reduction in revenue for drug companies, however, is one of the more controversial provisions in the law because it is expected to result in fewer new drugs being developed. A 2020 study estimated that the average cost of getting a new drug on the market is $1.3 billion.

The Congressional Budget Office estimates that the reduction of new drugs coming onto the market will be only a few a year.

"CBO estimates that under the bill, the number of drugs that would be introduced to the U.S. market would be reduced by about 2 over the 2023-2032 period, about 5 over the subsequent decade, and about 8 over the decade after that. CBO expects that under current law about 1,300 drugs will be approved over the next 30 years," a CBO report says.

The CBO, analyzing a more ambitious proposal in 2019 by House Speaker Nancy Pelosi that would have negotiated prices for more drugs, estimated that the Pelosi plan would reduce the number of new drugs coming onto the market by 8 to 15 new drugs over the next decade.

"The overall effect on the health of families in the United States that would stem from increased use of prescription drugs but decreased availability of new drugs is unclear," the CBO said.

While lower drug prices allow people to use more drugs, thereby aiding their health, lower drug prices also means that drug manufacturers will spend less money on research and development, reducing the supply of new drugs, the CBO explained.

Older

Serious questions remain in push for Medicare reform

Newer

Beyond Meat suspends COO after arrest for allegedly biting man's face

Advisor News

  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
  • Election results cloud retirement legislation outlook, experts say
  • Planning for the missing chapter
More Advisor News

Annuity News

  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
  • ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
  • Jackson Launches Direct-to-Consumer Annuity Offering
More Annuity News

Health/Employee Benefits News

  • Vt. public schools expect the lowest health insurance increase in years
  • Samantha Wildow: Mercy Health warns thousands of Medical Mutual of Ohio patients may go out-of-network in 2027
  • Reports Outline Managed Care Study Results from Harvard University (Inpatient-Only List Removals Shifted Procedures To The Outpatient Setting And Reduced Medicare Spending): Managed Care
  • Health and Humor: Picking a Medicare insurance plan is daunting
  • Obamacare is getting more expensive in Indiana
More Health/Employee Benefits News

Life Insurance News

  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • U-Haul Holding Company to Participate in Deutsche Bank Conference
  • NAIC task force to address LTC riders
  • Protective names Kurt Meyers Chief Legal Officer and Fernando Levy Chief Digital & AI Officer
  • Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.